BOC Sciences develops bone-targeted lipid nanoparticles (LNPs) through bone-affinity lipid engineering and targeting ligand functionalization, providing integrated support from lipid design and synthesis to LNP formulation, characterization, and bone delivery evaluation.
Bone-targeted LNPs are engineered to improve the delivery of therapeutic and research payloads to mineralized bone tissue and selected bone-associated cell populations. Unlike conventional LNPs that frequently accumulate in the liver, bone-targeting systems incorporate mineral-binding lipids, bisphosphonate groups, aspartate-rich peptides, or cell-recognition ligands to enhance interactions with bone tissue. These platforms are being investigated for mRNA expression, gene silencing, bone remodeling, osteoporosis research, and skeletal tissue regeneration.
BOC Sciences provides integrated targeted LNP development, covering bone-affinity lipid screening, targeting ligand synthesis, surface conjugation, payload encapsulation, formulation optimization, and cellular and in vivo evaluation. We support customized LNP development for mRNA, siRNA, miRNA, plasmid DNA, genome-editing components, and small-molecule payloads, with design strategies selected according to the intended bone site, target cell population, and delivery route.
Lipid Nanoparticle Delivery to Bone Tissue DiagramOur bone-targeted LNP development services integrate lipid chemistry, ligand engineering, nanoparticle formulation, and biological evaluation to address the challenges of delivering payloads to mineralized skeletal tissue. Projects can start with an existing LNP formulation, a candidate bone-homing ligand, or a defined bone-delivery objective. We customize the development strategy according to the payload, bone-associated target cells, ligand-binding mechanism, and intended administration route.
We investigate how ionizable lipid structures and bone-binding functional groups influence hydroxyapatite interactions, particle properties, cellular uptake, and tissue distribution.
We develop LNP surface modifications that promote interactions with bone mineral components or selected bone-associated cells. Ligand identity, conjugation chemistry, spacer length, surface density, and accessibility are evaluated together.
We integrate bone-targeting modifications with payload characteristics to develop LNP formulations that maintain loading performance, colloidal stability, and biological activity.
We evaluate bone affinity and functional delivery separately to determine whether candidate LNPs bind mineralized tissue, enter the intended cell population, and release biologically active payloads.
Bone-targeted LNPs can be developed through two major targeting mechanisms: mineral-directed binding and cell-specific recognition. Mineral-binding modifications, including bisphosphonate groups and aspartate-rich peptides, promote interactions with hydroxyapatite, the major mineral component of bone. In contrast, cell-recognition ligands such as osteoblast-binding aptamers are designed to improve uptake by selected bone-associated cells. BOC Sciences supports the synthesis, formulation, and comparative evaluation of these different targeting architectures.
Bisphosphonate-modified ionizable lipids integrate bone-mineral-binding groups directly into the ionizable lipid structure. Their phosphonate groups interact with calcium ions on hydroxyapatite surfaces, while the lipid backbone supports nanoparticle assembly and intracellular payload delivery. This design connects bone affinity with the intrinsic delivery functions of ionizable lipids.
Research reference: Yoon et al. reported piperazine-derived bisphosphonate-based ionizable lipids that improved hydroxyapatite binding and bone-microenvironment delivery following systemic administration (Angewandte Chemie International Edition, 2025).
Alendronate is a nitrogen-containing bisphosphonate with strong affinity for calcium-rich bone mineral surfaces. By connecting alendronate to a PEG-lipid anchor, it can be displayed on the LNP surface while the hydrophobic lipid portion associates with the nanoparticle. This architecture separates the mineral-binding function from the lipid assembly process.
Research reference: Xu et al. compared pre-conjugation and post-conjugation approaches for alendronate-functionalized LNPs. Their 2026 study reported stronger hydroxyapatite and isolated-bone binding with the post-conjugation strategy (Pharmaceutics, 2026).
Aspartate-rich peptides contain multiple negatively charged carboxylate groups that interact with calcium ions on hydroxyapatite surfaces. Their mineral affinity makes them useful surface ligands for directing LNPs toward bone tissue. Peptide-functionalized LNPs can therefore be designed to improve bone association without incorporating a bisphosphonate group directly into the ionizable lipid.
Research reference: Ren et al. reported Asp8-functionalized LNPs for anti-sclerostin antibody mRNA delivery. Their 2026 study evaluated hydroxyapatite binding, isolated-bone association, and in vivo bone accumulation, with reduced hepatic sequestration compared with conventional LNPs (Journal of Biomedical Materials Research Part A, 2026).
Aptamer-functionalized LNPs use short nucleic acid ligands to recognize selected cell-surface targets. Unlike mineral-binding strategies that primarily promote bone tissue accumulation, osteoblast-binding aptamers are designed to improve delivery to bone-forming cells. This approach is particularly relevant when the research objective requires cell-level selectivity and functional gene modulation.
Research reference: Liang et al. reported CH6 aptamer-functionalized LNPs carrying Plekho1 siRNA. The study demonstrated osteoblast-selective uptake and in vivo gene silencing associated with increased bone formation (Nature Medicine, 2015).
Share your target bone site, intended cell population, and payload. BOC Sciences can help compare mineral-binding lipids, bisphosphonate conjugates, peptide ligands, and cell-recognition strategies to identify a suitable development approach.
Bone-targeted LNPs can accommodate different payload classes depending on the intended biological mechanism and delivery objective. Nucleic acid payloads are particularly relevant to local protein expression and gene modulation, while small molecules and other bioactive components can be explored for bone remodeling and regeneration research. BOC Sciences connects payload selection with lipid composition, encapsulation strategy, bone-targeting modification, and functional evaluation.
| Payload Type | Supported Uses and Bone-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| Bone-Targeted LNP for mRNA | Designed for local protein expression, osteogenic signaling, and bone-associated gene modulation. Development focuses on mRNA integrity, encapsulation efficiency, mineral-binding functionality, and protein expression in bone-associated cells. Potential research payloads include anti-sclerostin antibody mRNA and mRNA encoding selected osteogenic regulators. Supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| Bone-Targeted LNP for siRNA | Suitable for gene-silencing studies involving osteoblast differentiation, bone formation, and bone remodeling pathways. Development evaluates siRNA encapsulation, target-cell uptake, intracellular release, and sequence-specific gene knockdown. Plekho1 siRNA has been investigated in osteoblast-targeted LNP research. Our lipid nanoparticles for siRNA delivery services support payload-specific formulation. | Inquiry |
| Bone-Targeted LNP for miRNA | Developed for investigating post-transcriptional regulation of osteoblast differentiation, osteoclast activity, and bone remodeling. Formulation considerations include RNA stability, encapsulation, intracellular release, and functional changes in selected bone-associated cells. Supported by our lipid nanoparticles for miRNA delivery capabilities. | Inquiry |
| Bone-Targeted LNP for pDNA and CRISPR Components | Applicable to gene-expression and genome-editing research in bone-associated cell populations. Development evaluates nucleic acid loading, particle stability, cellular uptake, and functional expression or editing readouts. Cas9 mRNA and guide RNA can be explored for transient genome-editing applications, while plasmid DNA may be considered for selected expression studies. Supported by our pDNA delivery and CRISPR-related LNP delivery capabilities. | Inquiry |
| Bone-Targeted LNP for Small Molecules | Designed for hydrophobic, amphiphilic, or ionizable compounds investigated in bone remodeling and regeneration research. Development focuses on drug-lipid compatibility, loading method, retention after surface modification, and release behavior. Valproic acid and tauroursodeoxycholic acid have been explored in bisphosphonate-functionalized LNP research. Supported by our small-molecule LNP delivery services. | Inquiry |
| Bone-Targeted LNP for Proteins and Peptides | Suitable for exploring the delivery of bioactive proteins, enzymes, and peptides involved in bone-associated signaling and tissue regeneration. Formulation development emphasizes mild loading conditions, protein stability, aggregation control, and preserved biological activity. Supported by our protein encapsulation in LNPs and peptide encapsulation in LNPs capabilities. | Inquiry |
| Bone-Targeted LNP for Co-Delivery | Developed for research requiring coordinated delivery of multiple payloads, such as combinations of nucleic acids and small molecules. Optimization considers loading sequence, payload compatibility, encapsulation efficiency, release behavior, and preservation of bone-targeting ligand accessibility. Our LNP co-delivery services support customized formulation development. | Inquiry |
| Bone-Targeted LNP for Custom Payloads | Developed for unusual payload structures, multi-component systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, bone-targeting modification route, particle stability, and delivery performance according to the specific research objective. | Inquiry |
Tell us your payload, intended bone site, target cell population, and delivery objective. BOC Sciences can help select a suitable lipid and ligand architecture and develop a formulation strategy around your research requirements.
Bone-targeted LNP projects can begin with an existing lipid formulation, a candidate mineral-binding ligand, or a defined skeletal delivery objective. We organize development into four practical stages, connecting lipid chemistry and formulation parameters with bone-binding and functional delivery evidence.

We review the intended skeletal site, target cell population, payload class, administration route, and desired biological readouts. The project may focus on mineralized bone surfaces, osteoblasts, osteocytes, or other bone-associated cells. These distinctions determine whether mineral-binding ligands, cell-recognition ligands, or combined targeting architectures should be investigated. We also define suitable non-targeted LNP controls and bone-versus-liver distribution endpoints.

We select candidate ionizable lipids, helper phospholipids, cholesterol, and PEG-lipids, then compare bisphosphonate-containing lipids, alendronate-PEG-lipid conjugates, Asp-rich peptides, and aptamer-based surface modifications. Lipid and ligand ratios are refined through structured LNP lipid ratio optimization. Each design includes appropriate non-targeted or alternative-ligand controls to distinguish mineral affinity from nonspecific particle accumulation.

Candidate formulations are prepared using suitable mixing and surface-modification methods. Microfluidic LNP production can be used to control mixing conditions and particle assembly. We compare particle size, PDI, zeta potential, morphology, payload encapsulation, and ligand incorporation. Purification and buffer exchange are then optimized to remove unbound ligands and residual formulation components while maintaining particle stability.

We first compare hydroxyapatite binding and interactions with isolated bone fragments, followed by cellular uptake and payload-specific functional evaluation. Selected candidates can undergo in vivo distribution studies to compare bone accumulation with liver, spleen, and other organ exposure. Nanoparticle in vivo distribution analysis helps determine whether improved mineral binding translates into measurable skeletal delivery. Findings are summarized in a comparative dataset with formulation tradeoffs and recommended next experiments.
A bone-targeted LNP may show strong hydroxyapatite binding yet still exhibit limited skeletal accumulation or insufficient functional delivery to bone-associated cells. We investigate lipid composition, ligand presentation, particle properties, and biological performance together to identify the factors limiting delivery.
✔ Low Bone Accumulation and Hepatic Sequestration
Conventional LNPs frequently show substantial hepatic uptake after systemic administration, limiting the fraction available for skeletal delivery. Bone-targeting ligands may improve mineral association, but their effectiveness depends on ligand accessibility, particle composition, and circulation behavior. We compare bisphosphonate-containing lipids, Asp-rich peptides, PEG-lipid content, and helper lipid ratios. Bone-to-liver distribution and tissue-associated payload expression are evaluated together rather than relying only on total fluorescence signals.
✔ Limited Bone Access and Tissue Penetration
Bone delivery involves more than binding to hydroxyapatite. Nanoparticles must reach skeletal tissue through the vascular compartment and interact with mineralized surfaces or accessible bone-associated cells. Excessive surface binding may also restrict movement beyond the initial binding region. We investigate particle size, surface charge, PEG architecture, and ligand density to balance tissue access with mineral affinity. Binding assays and spatial distribution measurements help distinguish effective skeletal access from surface-associated retention.
✔ Ligand-Related Instability and Reduced Payload Delivery
Introducing bisphosphonate groups, peptides, or aptamers can alter lipid packing, surface charge, particle size, and colloidal stability. Excessive ligand incorporation may also interfere with PEG shielding or reduce the accessibility of other functional components. We compare pre-conjugation and post-conjugation approaches, adjust spacer structures and ligand density, and monitor particle properties before and after modification. Formulation stability and payload retention are evaluated together to identify a suitable modification window.
✔ Bone Localization Without Functional Cell Delivery
Mineral binding does not necessarily indicate successful delivery into osteoblasts, osteocytes, or other target cells. Particles may remain associated with extracellular mineral surfaces without releasing their payload into the cytoplasm. We distinguish tissue accumulation, cellular internalization, intracellular localization, and functional expression or gene silencing using complementary readouts. When post-uptake delivery remains limiting, LNP endosomal escape evaluation helps investigate intracellular barriers and guide subsequent lipid or ligand optimization.
Share your current lipid composition, targeting ligand, payload, and evaluation results. BOC Sciences can help identify formulation limitations and develop a focused optimization strategy for bone affinity and functional delivery.
Bone-targeted LNPs provide opportunities to investigate gene regulation, local protein expression, and bioactive compound delivery in skeletal tissues. Their applications depend on whether the targeting system is designed for mineralized bone accumulation or direct recognition of selected bone-associated cells. BOC Sciences supports customized LNP development for the following research areas, with payload and ligand selection matched to the intended biological mechanism.
Tell us your intended skeletal application, target cell population, payload, and delivery requirements. BOC Sciences can help design, synthesize, formulate, and evaluate bone-targeted LNPs using suitable lipid and ligand engineering strategies.
We support project-specific sourcing and preparation of lipid materials for nanoparticle and liposome research, including ionizable lipids, cationic lipids, helper phospholipids, cholesterol, PEG-lipids, and functional lipid conjugates. Material selection is matched to the intended carrier architecture, formulation method, and payload requirements. We also support customized lipid building blocks and functional intermediates for specialized bone-targeting designs.

We connect ionizable lipid structure, bisphosphonate functionality, PEG-lipid architecture, and peptide or aptamer modification with bone-binding performance. This allows us to develop and compare different mineral-directed and cell-recognition strategies instead of relying on a single fixed targeting platform.
Our capabilities cover lipid conjugate preparation, custom synthesis, nanoparticle assembly, ligand coupling, and post-formulation modification. We can investigate pre-conjugation and post-conjugation routes and optimize ligand density, spacer accessibility, and particle composition according to the intended bone-targeting mechanism.
Particle characterization, hydroxyapatite binding, cellular uptake, functional payload delivery, and in vivo distribution can be incorporated into one development program. This integrated approach helps distinguish mineral affinity from cell-specific delivery and connects formulation changes with measurable biological outcomes.
From lipid and ligand selection to custom synthesis, LNP formulation, characterization, and delivery evaluation, we coordinate the major development stages within one project plan. Our team helps identify formulation limitations, compare alternative targeting strategies, and refine candidate designs according to your research objectives.
Bone-targeted lipid nanoparticles achieve skeletal accumulation through surface modifications or specialized lipid structures that interact with mineralized bone tissue. Bisphosphonate groups, alendronate conjugates, and aspartate-rich peptides can bind calcium-rich hydroxyapatite surfaces, promoting particle association with bone. Alternatively, cell-recognition ligands, such as osteoblast-binding aptamers, are designed to improve uptake by specific bone-associated cells. BOC Sciences supports the development of these systems through bone-affinity lipid design, ligand synthesis, surface functionalization, and formulation optimization. Importantly, bone accumulation and functional intracellular delivery require separate evaluation.
Several ligand classes have been investigated for bone-targeted LNP development. Bisphosphonates, including alendronate, provide mineral affinity through interactions with calcium-rich hydroxyapatite. Aspartate-rich peptides, such as Asp8, use multiple carboxylate groups to promote bone mineral binding. For cell-specific delivery, osteoblast-binding aptamers such as CH6 offer a different recognition mechanism. These ligands differ in binding characteristics, conjugation requirements, and biological targets. BOC Sciences supports peptide and aptamer synthesis, bisphosphonate-lipid conjugation, PEG-lipid modification, and comparative screening to identify suitable targeting architectures for individual delivery projects.
Hydroxyapatite-binding LNPs are designed by incorporating mineral-affinity groups into ionizable lipids or attaching bone-binding ligands to the particle surface. Representative approaches include bisphosphonate-containing ionizable lipids, alendronate-conjugated PEG-lipids, and Asp8-functionalized LNPs. Development involves optimizing ligand structure, surface density, lipid composition, and particle characteristics. Evaluation typically includes hydroxyapatite-binding assays, interactions with isolated bone fragments, particle characterization, and cellular uptake studies. Subsequent animal studies can compare skeletal accumulation with liver and spleen distribution. BOC Sciences supports lipid synthesis, conjugation, formulation, and integrated bone-binding and delivery evaluation.
Bone-targeted LNPs can be developed for mRNA, siRNA, miRNA, plasmid DNA, and genome-editing components, as well as selected small molecules, proteins, and peptides. These payloads support different research objectives, including osteogenic protein expression, gene silencing, bone remodeling studies, and skeletal tissue regeneration. Formulation requirements depend on payload size, charge, structural stability, and intended intracellular activity. For example, mRNA and siRNA require different loading and functional evaluation strategies, while proteins may require additional attention to aggregation and activity retention. BOC Sciences provides customized payload encapsulation, lipid composition optimization, and functional delivery evaluation.
Bone accumulation and functional cellular delivery represent different stages of nanoparticle performance. Bone accumulation can be evaluated through hydroxyapatite-binding assays, isolated-bone association, and tissue biodistribution studies comparing skeletal accumulation with liver and spleen exposure. Cellular delivery requires additional measurements, including uptake by osteoblasts or other selected bone-associated cells, intracellular localization, and functional readouts such as reporter expression or target-gene silencing. A formulation may show strong mineral binding without efficiently releasing its payload inside target cells. BOC Sciences integrates physicochemical characterization, bone-affinity testing, cellular uptake analysis, and evaluation to investigate these stages separately.